Unión Europea -
finés -
EMA (European Medicines Agency)
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiset aineet - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
Finlandia -
finés -
Fimea (Suomen lääkevirasto)
puma extra
bayer ag - magnesium varten,liuosta varten-geeli. haihtua,methylpolysiloxan - tabletti - antasideja ja kaasunmuodostusta vähentäviä lääkeaineita sisältävät yhdistelmävalmisteet
Finlandia -
finés -
Fimea (Suomen lääkevirasto)
lyrinel 5 mg depottabletti
janssen-cilag oy - oxybutynini hydrochloridum - depottabletti - 5 mg - oksibutiniini
Finlandia -
finés -
Fimea (Suomen lääkevirasto)
lyrinel 10 mg depottabletti
janssen-cilag oy - oxybutynini hydrochloridum - depottabletti - 10 mg - oksibutiniini
Finlandia -
finés -
Fimea (Suomen lääkevirasto)
lyrinel 15 mg depottabletti
janssen-cilag oy - oxybutynini hydrochloridum - depottabletti - 15 mg - oksibutiniini